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Insulin resistance has been associated with kidney disease
even in the absence of diabetes; however, pathways linking
insulin resistance to kidney disease are unclear. The purpose
of this study was to determine if transforming growth factor
(TGF)-b1, a key cytokine associated with kidney disease,
responds to circulating levels of glucose and/or insulin.
Urinary TGF-b1 levels were measured in 249 young adult
African Americans (mean age 40) at baseline, after an oral
glucose tolerance test and after a euglycemic
hyperinsulinemic clamp procedure. Baseline urinary
geometric mean TGF-b1 levels were somewhat lower in those
with normal compared with the impaired glucose tolerance.
The urinary TGF-b1 level increased by 56% followed by a 23%
decrease in the normal glucose tolerance group, changes
that were significant and corresponded to the changes in the
plasma glucose and insulin concentrations. The impaired
tolerance group showed little change in the urinary TGF-b1
level following glucose ingestion. All participants had a
significant increase in urinary TGF-b1 level after steady-state
hyperinsulinemia, with sustained euglycemia during the
clamp procedure in both of the groups. At baseline, there
was a significant correlation between the urinary TGF-b1 level
and urinary albumin excretion. Thus our results suggest that
insulin contributes to increased TGF-b1 production and
possible early renal injury in prediabetic young African
Americans.
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Diabetes is a leading cause of end-stage kidney disease in the
United States.1 African Americans develop diabetic nephro-
pathy at a disproportionately greater rate compared with
Caucasians.2 The Pathological characteristics of diabetic
nephropathy include thickening of glomerular and tubular
membranes, and subsequent accumulation of extracellular
matrix components resulting in fibrosis. Transforming
growth factor (TGF)-b1 is a tissue cytokine with fibrogenic
properties.3 A convincing body of experimental studies have
demonstrated high levels of TGF-b1 in kidney cells of
diabetic rodents,4 and attenuation of matrix deposition in the
renal tissue of diabetic rodents with exposure to anti-TGF-b1
antibodies.5,6
Although experimental studies have developed consider-
able evidence implicating an increase in TGF-b1 activity as a
key mediator in the pathogenesis of diabetic nephropathy,7
there are limited data on the role of TGF-b1 in the
pathogenesis of diabetic nephropathy in humans. In a small
sample of patients undergoing cardiac catheterization, the
concentration of TGF-b1 in samples from the renal vein
compared with samples from the aorta was elevated in
diabetic patients but not in non-diabetic patients, indicating
greater local renal production of TGF-b1 in the diabetic
patients.8 The net renal production of TGF-b1 across the
renal vascular bed was associated with increased urinary
levels of TGF-b1. In another clinical study, urinary TGF-b1
level was measured in healthy non-diabetic volunteers
following a constant glucose infusion to achieve sustained
hyperglycemia. Following 120min of modest hyperglycemia
(200–225mg/dl), there was a marked increase in urinary
TGF-b1 level without a corresponding increase in the plasma
TGF-b1 concentration.9 Together, these reports indicate that
both diabetes and episodes of hyperglycemia are associated
with upregulation of TGF-b1 activity in the kidney. The
purpose of this study was to determine whether renal TGF-b1
production, estimated by urinary TGF-b1 level, responds to
modest increases in plasma insulin. Our study was designed
to test the hypothesis that urinary TGF-b1 levels are greater
in prediabetic African Americans, and that urinary TGF-b1
levels increase following glucose and/or insulin exposure.
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RESULTS
The study cohort consisted of 249 participants, who were
stratified as having normal glucose tolerance (NGT; N¼ 176)
and impaired glucose tolerance (IGT; N¼ 73) based on their
fasting blood glucose and oral glucose tolerance test (OGTT)
results according to the American Diabetes Association
criteria.10 Table 1 provides the clinical characteristics of the
study participants. The mean age of the cohort was 40 years
and there was no significant age difference between the NGT
and IGT groups. In the whole study sample, 62% were
females and 51% were self-identified cigarette smokers. The
mean body mass index values for both NGT and IGT groups
were in the obese range (body mass index X30 kg/m2).
However, the IGT group had a significantly higher mean
body mass index value than the NGT group. The mean
systolic and diastolic blood pressure (BP) values of the cohort
were in the normotensive range and there was no significant
difference between the NGT and IGT groups.
Table 2 presents the means and standard deviations of
plasma glucose and insulin measurements during the OGTT,
for both the NGT and IGT groups. The two groups had
significantly different fasting and 2-h OGTT glucose levels,
consistent with our classification system. Insulin levels at 2-h
post glucose ingestion were also significantly different
between the two groups. In the NGT group, the plasma
insulin levels peaked between 30–60min and subsequently
decreased at 2 h post glucose ingestion. In the IGT group,
however, the plasma insulin levels remained elevated at 2 h
after glucose ingestion.
Table 2 also shows the results of the insulin-clamp
procedure. The mean clamp glucose level was similar to the
basal glucose level in both NGT and IGT groups, indicating
that sustained euglycemia was achieved during clamp
hyperinsulinemia. The achieved steady-state hyperinsuline-
mia (mean clamp insulin) was somewhat higher in the IGT
group than in the NGT group. The glucose infusion rate,
which quantifies the insulin-mediated glucose uptake, was
higher in the NGT group than in the IGT group. The insulin
sensitivity index (M/I, where M is the mean glucose infusion
rate and I is the mean plasma insulin concentration) derived
from the insulin clamp showed a clear separation of insulin
sensitivity according to the glucose tolerance state; the NGT
group had significantly higher M/I than the IGT group.
Table 3 presents the geometric means and interquartile
ranges of urinary TGF-b1 level (in picograms per milligram
creatinine) and urinary albumin excretion (UAE, in milli-
grams per gram creatinine) during the OGTT and insulin-
clamp procedure, for both the NGTand IGT groups. Figure 1
is a graph of the estimated geometric means and 95%
confidence intervals for the urinary TGF-b1 level during the
OGTT and insulin clamp, for the two groups. There were
significant differences between the NGT and IGT
groups in the overall pattern of urinary TGF-b1 level during
the OGTT (P¼ 0.038), but not during the insulin clamp
(P¼ 0.404).
In analyses that adjusted for age, sex, smoking, alcohol
use, obesity, hypertension, and UAE, the NGT group had an
estimated 56% increase in urinary TGF-b1 level at 2 h post
glucose ingestion compared with baseline (P¼ 0.001) and a
subsequent 23% decrease from 2 to 4 h post glucose ingestion
(P¼ 0.025). The IGT group showed a 2% decrease from
baseline to 2 h post glucose ingestion (P¼ 0.902) and a 10%
increase from 2 to 4 h post glucose ingestion (P¼ 0.598). The
NGT and IGT groups were significantly different with regard
to the change from baseline to 2 h post glucose ingestion
(þ 56% versus 2%, P¼ 0.019) and marginally so with
regard to the change from 2 to 4 h post glucose ingestion
(23% versus þ 10%, P¼ 0.096). For UAE, the NGT group
had 68% increase at 2 h post glucose ingestion compared
with baseline (P¼ 0.001) and a subsequent increase of 99%
from 2 to 4 h post glucose ingestion (P¼ 0.001). The IGT
group had 67% increase at 2 h post glucose ingestion
compared with baseline (P¼ 0.012) and a 38% increase
from 2 to 4 h post glucose ingestion (P¼ 0.064). There were
no significant differences between the NGT and IGT groups
in terms of change in UAE from baseline to 2 h (P¼ 0.970)
and from 2 to 4 h post glucose ingestion (P¼ 0.077).
Following the insulin-clamp procedure, there was a
significant increase in urinary TGF-b1 level in both NGT
(42%, P¼ 0.008) and IGT (95%, P¼ 0.001) groups, com-
pared with baseline (after adjustment for age, sex, smoking,
alcohol use, obesity, hypertension, and UAE). The magnitude
of these increases, however, was not statistically different
between the two groups (P¼ 0.200). Despite the marked
increase in urinary TGF-b1 following the exposure to
euglycemic hyperinsulinemia, the post-clamp UAE values in
both NGT and IGT groups were essentially unchanged
Table 1 | Characteristics of study subjects
Characteristic (mean±s.d.)
All
(N=249)
NGT
(N=176)
IGT
(N=73) Pa
Age (years) 40±3.4 40±3.3 40±3.6 0.89
0.32
Sex, n (%)
Male 94 (38) 70 (40) 24 (33)
Female 155 (62) 106 (60) 49 (67)
Smoking, n (%) 0.04
No 123 (49) 79 (45) 44 (60)
Yes 126 (51) 97 (55) 29 (40)
BMI (kg/m2) 30.9±7.2 30.3±7.0 32.2±7.5 0.06
Obesity, n (%) 0.21
Normal weight 55 (22) 44 (25) 11 (15)
Overweight 73 (29) 51 (29) 22 (30)
Obese 121 (49) 81 (46) 40 (55)
SBP (mmHg) 125±20 124±21 126±18 0.46
DBP (mmHg) 73±13 74± 14 73±11 0.70
Hypertensionb, n (%) 79 (32) 54 (31) 25 (34) 0.65
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; IGT, impaired
glucose tolerance; NGT, normal glucose tolerance; SBP systolic blood pressure.
aP-values are based on Fisher’s exact test for categorical variables and analysis of
variance for continuous variables.
bHypertension is defined as X140/90 or on antihypertensive medication.
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compared with baseline (P¼ 0.22 and P¼ 0.92, respectively).
There was no significant difference between the NGTand IGT
groups in terms of change in UAE from baseline to post
hyperinsulinemic clamp (P¼ 0.573).
The changes in urinary TGF-b1 level during the insulin
clamp were further analyzed according to three insulin
sensitivity levels based on the M/I values (o5¼ resistant,
5–7.5¼ intermediate, and 47.5¼ sensitive). The increase in
the urinary TGF-b1 level at the end of the clamp compared
with baseline appeared to be greatest in the insulin-resistant
group (2.25-fold increase, P¼ 0.001), intermediate in the
intermediate group (79% increase, P¼ 0.020), and lowest in
the insulin sensitive group (33% increase, P¼ 0.062).
However, despite the trend of greater increase in urinary
TGF-b1 level following hyperinsulinemia with insulin
resistance, analyses compare the change in slope did not
detect a statistically significant difference between the three
insulin sensitivity groups (P¼ 0.114).
As shown in Table 4, there were also significant
correlations between baseline urinary TGF-b1 level and
UAE in both OGTT and the clamp study, supporting the
role of urinary TGF-b1 level in early renal injury. The
correlation coefficient for UAE measured in the two baseline
urine samples in OGTT and the clamp study was 0.505
(P¼ 0.001), indicating a high level of consistency within
subjects for measurements of UAE.
Table 2 | Glucose, insulin, and insulin sensitivity measurements during the OGTT and insulin clamp
Measurements during the OGTT (mean±s.d.) NGT (N=176) IGT (N=72) Pa
Glucose OGTT baseline (mg/dl) 98±8 102±11 0.001
Glucose OGTT 30min (mg/dl) 155±34 165±29 0.025
Glucose OGTT 60min (mg/dl) 154±35 186±32 0.001
Glucose OGTT 120min (mg/dl) 105±24 158±16 0.001
Insulin OGTT baseline (mU/ml) 9±8 11±8 0.06
Insulin OGTT 30min (mU/ml) 72±46 75±64 0.71
Insulin OGTT 60min (mU/ml) 78±55 92±61 0.08
Insulin OGTT 120min (mU/ml) 40±36 92±57 0.001
Measurements during the insulin clamp (mean±s.d.) (N=168) (N=67) Pa
Basal glucoseb (mg/dl) 88±7 92±7 n/ab
Basal insulin (mU/ml) 8±7 11±10 0.021
Mean clamp glucose (mg/dl) 87±9 91±8 0.001
Mean clamp insulin (I) (mU/ml) 73±27 81±28 0.05
Mean glucose infusion rate (M) (mg/kg/min) 6.3±2.7 4.9±2.4 0.001
M/I 100 10.3±6.8 7.4±5.6 0.002
Abbreviations: IGT, impaired glucose tolerance; NGT, normal glucose tolerance; OGTT, oral glucose tolerance test.
aP-values are based on analysis of variance.
bFor subjects with fasting glucose greater than 100mg/dl, the basal glucose level was fixed at 100mg/dl for the clamp.
To convert glucose to SI units, multiply by 0.05551. To convert insulin to SI units, multiply by 7.175.
Table 3 | Urinary TGF-b1 level and UAE during the OGTT and insulin clamp
During the OGTT (geometric means and interquartile ranges) NGT (N=176) IGT (N=73) Pa
Urinary TGF-b1 (pg per mg creatinine)
Baseline 0.8 (0.4, 1.9) 1.3 (0.8, 2.7) 0.02
2 h 1.3 (0.6, 3.3) 1.3 (0.6, 3.0) 0.76
4 h 1.0 (0.4, 2.5) 1.4 (0.7, 3.4) 0.04
UAE (mg per g creatinine)
Baseline 0.9 (0.3, 3.1) 0.8 (0.3, 2.7) 0.84
2 h 1.5 (0.5, 3.6) 1.4 (0.5, 3.2) 0.73
4 h 2.9 (1.0, 7.3) 1.9 (0.6, 6.1) 0.06
During the insulin clamp (geometric means
and interquartile ranges)
NGT (N=171) IGT (N=68) Pa
Urinary TGF-b1 (pg per mg creatinine)
Baseline 1.1 (0.5, 2.6) 1.0 (0.6, 1.9) 0.53
Post-clamp 1.6 (0.7, 3.8) 1.9 (0.7, 3.6) 0.39
UAE (mg per g creatinine)
Baseline 1.3 (0.3, 4.4) 1.8 (0.6, 6.6) 0.23
Post clamp 1.6 (0.6, 4.2) 1.7 (0.6, 4.0) 0.71
Abbreviations: IGT, impaired glucose tolerance; NGT, normal glucose tolerance; OGTT, oral glucose tolerance test; TGF-b1, transforming growth factor; UAE, urinary albumin
excretion.
aP-values are based on t-tests for the log-transformed TGF-b1 measurements.
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DISCUSSION
Data from this study indicate that following insulin exposure
there is an increase in urinary TGF-b1 in young adult African
Americans without clinical diabetes. Participants with NGT
had somewhat lower baseline urinary TGF-b1 levels than
those with IGT and responded to the glucose challenge with
an increase followed by a decrease in urinary TGF-b1 level.
Participants with IGT had no significant changes in the
urinary TGF-b1 level in response to the oral glucose
challenge. During the insulin clamp, both NGT and IGT
groups had significant increases of comparable magnitude in
urinary TGF-b1 level following the exposure to hyperinsu-
linemia without change in plasma glucose concentration.
Together, these findings suggest that insulin has a role in
upregulating the TGF-b1 production. Baseline urinary
TGF-b1 level was also correlated significantly with UAE, a
valid marker of renal injury. There was no increase in
UAE following the insulin clamp, indicating that the increase
in urinary TGF-b1 following the insulin clamp was not due
to leakage of circulating TGF-b1 into the urine.
Experimental studies have implicated TGF-b1 in the
pathogenesis of diabetic nephropathy.7,11 In kidneys of
diabetic rodents, there is evidence of upregulation of renal
TGF-b1, its receptors, and intracellular signaling pathway
resulting in collagen deposition and tissue fibrosis.4–6,12–18 In
diabetic mice, treatment with neutralizing anti-TGF-b1
antibodies prevented the development of renal hypertrophy,
mesangial expansion, and renal function deterioration.6
Limited human data are available on TGF-b1 in type 2
diabetes and diabetic nephropathy. Yamamoto et al.19
examined TGF-b1 expression in renal tissues from six
patients with advanced diabetic glomerulosclerosis compared
with three normal controls, three cases of minimal change
disease, and three cases of thin basement membrane disease.
They reported that renal tissue from diabetic patients had
markedly higher levels of TGF-b1 expression compared with
normal controls, whereas that from patients minimal change
disease and thin basement membrane disease had similar
levels of TGF-b1 expression as normal controls. In a study of
44 type 2 diabetic patients and 28 non-diabetic controls,
Pfeiffer et al.20 reported a higher plasma TGF-b1 level in the
diabetic patients compared with non-diabetic controls. There
was also a significant correlation between plasma TGF-b1
and hemoglobin A1c level. In a subsequent study of similar
size, the same group reported that type 2 diabetic patients
with nephropathy had a higher circulating level of an
activated form of TGF-b1 than type 2 diabetic patients
without nephropathy.21 Sharma et al.8 measured plasma
TGF-b1 concentration in the aorta and renal vein during
elective cardiac catheterization in 14 type 2 diabetic and 11
non-diabetic patients. In diabetic patients, the concentration
of TGF-b1 in the renal vein was greater than in the aorta,
whereas in non-diabetic patients, the TGF-b1 concentration
in the renal vein was lower than in the aorta. In addition, they
reported greater urinary TGF-b1 level in diabetic patients.
These results indicated that there was increased local renal
production of TGF-b1 in type 2 diabetes that could be
estimated by the urine levels. Sato et al.22 reported higher
urinary TGF-b1 level in 57 diabetic patients compared with
20 healthy controls. In addition, they found that higher
urinary TGF-b1 levels were associated with higher hemoglo-
bin A1c levels and greater mesangial expansion on renal
biopsy. Data from our study extend these findings to the
prediabetic condition, with detection of increased urinary
TGF-b1 levels in those with only IGT.
Glucose exposure has been suggested as a key mediator in
upregulating TGF-b1 activity. In vitro studies have shown an
increase in TGF-b1 expression and bioactivity in renal cells
when exposed to high glucose concentration.23–27 In diabetic
rodents, the expression of TGF-b1 mRNA and protein in
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Figure 1 | The estimated geometric means and 95%
confidence intervals for urine transforming growth factor
(TGF)-b1 for the normal glucose tolerance (NGT) group
(box connected by green line) and the impaired glucose
tolerance (IGT) group (diamond connected by pink line).
The values during the oral glucose tolerance test (OGTT) are
plotted on the left side and the values before and after the insulin
clamp on the right side.
Table 4 | Correlations between baseline urinary TGF-b1 level
and urinary albumin excretion (UAE)
Baseline urinary TGF-b1 and UAE Correlationa P
OGTT baseline 0.209 o0.001
Clamp baseline 0.317 o0.001
Abbreviations: OGTT, oral glucose tolerance test; TGF-b1, transforming growth
factor-b1; UAE, urinary albumin excretion.
aCorrelations are Pearson’s correlations between urinary TGF-b1 and UAE values.
Both urinary TGF-b1 and UAE are corrected for creatinine and log-transformed.
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renal tissues was also reported to increase within 3 days after
the onset of overt diabetes with hyperglycemia.4 In a previous
clinical study, normal volunteers were exposed to steady-state
hyperglycemia using a glucose-clamp procedure.9 After
120min of steady-state hyperglycemia (200–250mg/dl), there
were significant increases in urinary TGF-b1 level in the
normal (non-diabetic) individuals. In this acute study, the
increase in urinary TGF-b1 level seemed to be in response to
the prolonged hyperglycemia. However, during hyperglyce-
mia, there was also a progressive and substantial increase in
endogenous insulin production. In these normal individuals,
the mean insulin concentration reached 98 mU/ml at the end
of the glucose clamp. Despite the substantial acute increase in
urinary TGF-b1, there was no increase in plasma TGF-b1. In
this study, the NGT group had an increase followed by a
decrease in urinary TGF-b1 level during the OGTT,
corresponding to the changes in plasma glucose and insulin
concentrations.
Hyperinsulinemia associated with insulin resistance is
characteristic of type 2 diabetes and also of prediabetes. In
our study, both NGT and IGT groups had a significant
increase in urinary TGF-b1 level in response to the steady-
state hyperinsulinemia with the plasma glucose concentration
clamped at the fasting level of less than 100mg/dl. The
marked increase in urinary TGF-b1 cannot be simply
explained by increased urinary leakage, as UAE was
essentially unchanged after the insulin clamp in both NGT
and IGT groups. These results indicate that, in humans,
insulin has a more direct role in upregulating TGF-b1
activity. Our findings are consistent with a previous study by
Ellis et al.28 on 46 type 1 diabetic patients. They reported a
significant correlation between urinary TGF-b1 level and
exogenous insulin dose but not glycemic control, also
suggesting that insulin stimulates TGF-b1 activity.
Our data show some association between insulin resis-
tance and increase in urinary TGF-b1 level following
hyperinsulinemia. This observation suggests that increased
TGF-b1 response to insulin may occur in patients before the
onset of clinically evident type 2 diabetes. Romano et al.29
used the Bergman minimal model approach to measure
insulin sensitivity in obese women. These investigators found
an association between the plasma TGF-b1 level and M/I,
which is consistent with our finding that insulin resistance is
associated with a greater increase in urinary TGF-b1 level.
Yener et al.30 measured plasma TGF-b1 levels in women with
a history of gestational diabetes (a prediabetic state), type 2
diabetes, and in healthy controls. They reported significantly
higher plasma TGF-b1 levels in women with gestational
diabetes than in the normal women and highest plasma
TGF-b1 levels in women with type 2 diabetes. These previous
reports also indicate a relationship between insulin resistance
and increased TGF-b1 activity.
African Americans have a greater prevalence of end-stage
kidney disease compared with Caucasians.2 A study by
Suthanthiran et al.31 examined the clinical risk factors for
renal disease in African and Caucasian Americans. In both
normotensives and hypertensives, serum TGF-b1 levels were
higher in African-Americans compared with Caucasians.
These authors reported significantly stronger associations in
African Americans than in Caucasians between serum TGF-b1
level and renal disease risk factors, including BP, metabolic
syndrome, and microalbuminuria. Although serum TGF-b1
levels are contributed by platelets and may have high
variability due to sample preparation, the observations are
consistent with our finding that urinary TGF-b1 levels are
increased in African Americans.
While our study is based on a cohort of relatively
young adult African Americans without overt diabetes or
nephropathy, it is the largest available clinical study on TGF-b1
in an ethnic group at higher risk for type 2 diabetes and
diabetic nephropathy. We observed considerable variability
within urinary TGF-b1 measurements. The Pearson’s correla-
tion coefficient between the two fasting urinary TGF-b1
measurements before the OGTT and insulin-clamp proce-
dure was only r¼ 0.334 (Po0.05). Based on the variability in
urinary TGF-b1, we are interpreting with caution the
significance of the difference in baseline urinary TGF-b1
between the NGT and IGT groups. A limitation of our study
is that we did not measure TGF-b1 levels in plasma.
In our previous study,9 no changes were observed in plasma
TGF-b1 concentration despite a marked increase in urinary
TGF-b1 level following sustained hyperglycemia and en-
dogenous hyperinsulinemia. However, that study was con-
ducted on a small sample of Caucasian subjects who were
acutely exposed to hyperglycemia. It is possible that chronic
relative hyperinsulinemia in the IGT group in this study
could have caused increases in plasma TGF-b1 level that we
failed to detect.
Data from this study show higher urinary TGF-b1 level in
the prediabetic state and an increase in urinary TGF-b1 level
following an increase in plasma insulin level. These data
suggest that insulin upregulates TGF-b1 activity, and that
both insulin and TGF-b1 contribute to the pathogenesis of
diabetic nephropathy. Our data also indicate that the process
may be operational at an early phase, before the onset of
clinically evident diabetes.
MATERIALS AND METHODS
Subjects
Participants in this study were drawn from a cohort of healthy
young adult African Americans enrolled in a longitudinal study of
BP and risks for cardiovascular and renal injury. The participants
were all self-identified African Americans recruited from urban
Philadelphia and were previously examined between 1994 and 1999.
Exclusion criteria at that time included known type 1 and 2 diabetes,
polycystic ovarian syndrome, and chronic kidney disease. The
participants were re-enrolled for this project between August 2001
and July 2007. Individuals who developed type 2 diabetes
subsequent to the previous enrollment, as well as participants
found to be diabetic on re-examination, were excluded from the
data analyses. Written informed consent was obtained from each
participant at the time of re-enrollment on an institutionally
approved protocol and consent form.
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Procedures
Each participant was examined on two separate visits, 4–8 weeks
apart. Instructions were given to collect a timed overnight urine
sample on the morning of both visits. Clinical assessment at both
visits consisted of anthropometric measurements (height and
weight), BP and fasting blood samples. An oral glucose tolerance
test (OGTT) was performed on the first visit and a euglycemic
hyperinsulinemic clamp was performed on the second visit. Body
mass index was calculated as weight (kg) divided by height squared
(m2). The BP measurements were obtained on each subject after a
10-min rest period in a seated position using auscultation with a
mercury column sphygmomanometer. The average of two successive
readings of systolic and diastolic BP (Korotkoff phase V) was used as
the BP value of each visit.
The OGTTwas conducted after a 12-h overnight fast. The fasting
blood sample was obtained for plasma insulin and glucose
concentrations before the ingestion of 75 g of glucose solution
(Glucola; Ames Diagnostics, Elkhart, IN, USA). Blood samples were
then obtained at 30, 60, and 120min post-ingestion and assayed for
plasma insulin and glucose concentrations. Plasma glucose con-
centration was analyzed with the glucose oxidase technique (YS
Model 27; Glucostat, Yellow Springs, OH, USA). Plasma insulin
concentration was determined with a solid-phase radioimmunoas-
say (Coat-a-Count; Diagnostic Products Corp, Los Angeles, CA,
USA). Coefficients of variation for intra- and inter-assay variability
for glucose and insulin assays were o5%.
The euglycemic hyperinsulinemic clamp was carried out as
described previously.32–34 In brief, all subjects were required to have
a 12-h overnight fast before the insulin clamp procedure. Blood
samples were obtained for baseline plasma glucose and insulin
concentration. Hyperinsulinemia was established with a primed
constant infusion of insulin (Eli Lilly, Indianapolis, IN, USA) at a
concentration of 1000mU/ml in normal saline according to the
method of Rizza et al.33 The primed infusion rate was sufficient to
achieve steady-state hyperinsulinemia at 80–120mU/ml above fasting
insulin levels with the aim of suppressing hepatic glucose
production. Hyperinsulinemia was maintained for 120min, during
which time the plasma glucose concentration was maintained at the
fasting (baseline) level using a variable infusion of 20% dextrose in
water (Abbott Lab, Abbott Park, IL, USA). For participants with
elevated fasting glucose greater than 110mg/dl, the baseline glucose
level at 100mg/dl was set as the target euglycemic level. The glucose
infusion rate was adjusted by the negative feedback equation of
DeFronzo et al.,32 according to the plasma glucose level sampled
every 10min. The calculated mean value of M (in mg/kgmin)
during the final 60min of the clamp procedure was the measure of
insulin-mediated glucose uptake, or insulin sensitivity. M was
adjusted for the level of steady-state hyperinsulinemia in each case
by dividing M by I during the final 60min of the clamp procedure to
derive the M/I (in mg/kgmin  100).
A timed overnight urine sample was collected from each
participant at both visits. The volume and collection time were
recorded for each urine sample. On the first visit, each participant
was asked to void before ingesting the glucose load for the OGTT.
Two additional urine samples were then collected at 2 h (2-h OGTT)
and 4 h after the glucose ingestion. On the second visit, each
participant was asked to void before starting the insulin clamp. One
additional urine sample was collected at the end of the insulin-
clamp study. All urine samples were assayed for albumin, creatinine,
and TGF-b1. Urine albumin concentration was analyzed by enzyme-
linked immunosorbent assay using an Albuwell kit (Exocell,
Philadelphia, PA, USA) according to the manufacturer’s instruc-
tions. Urine creatinine concentration was assayed using a NOVA
analyzer (NOVA Biomedical, Waltham, MA, USA). Urine albumin
excretion was computed in micrograms per minute and in
milligrams per gram creatinine.
TGF-b1 measurements
TGF-b1 in urine was assayed by a method previously described and
developed by Siva and Dunn.35 This assay uses a sandwich enzyme-
linked immunosorbent assay (Quantikine kit for human TGF-b1
immunoassay; R&D Systems, Minneapolis, MN, USA). In brief, a
10-ml aliquot of urine stored at 801C in a polypropylene tube
without preservatives was thawed overnight in a refrigerator and
centrifuged gently to remove sediments. Duplicates of 2-ml aliquot
from each urine sample were made acidic (pHo2) by the addition
of hydrochloric acid to activate latent TGF-b1 to the active form.
After at least 15min, the urine samples were adjusted to pH 7.3±0.3
with sodium hydroxide. The duplicates were concentrated to less
than 200ml using a Centricon filter unit (YM-10; Millipore, St.
Charles, MO, USA) and the final volume of each sample was
adjusted to 200 ml to achieve a concentration factor of 10 using a
buffer from the Quantikine kit for human TGF-b1 immunoassay
(R&D System). Corrections were made for urine concentration by
measuring net urine creatinine, and values were expressed as TGF-
b1 in picograms per milligram creatinine. The correlation coefficient
with standards is40.98 and the lowest detectable limit for TGF-b1
measurement is 0.7 pg/ml. The reliability of this assay for urinary
TGF-b1 is high with an intra- and inter-assay coefficients of
variation of 2.5±3.0% and 5.6±4.2%, respectively. The recovery of
fortified TGF-b1 added to the urine samples was 94%. No
interference from TGF-b2 was observed.
Statistical analysis
The cohort was stratified into two groups of different glucose
tolerance status, NGT, and IGT, according to the American Diabetes
Association criteria10 based on their fasting glucose and OGTT
results. To avoid over-classification of IGT based on a single isolated
elevated fasting blood glucose level close to the threshold of 100mg/
dl, the NGT group was defined as having a fasting blood glucose level
less than 126mg/dl and 2 h OGTT less than 140mg/dl, whereas the
IGT group was defined as having a fasting blood glucose level less
than 126mg/dl and 2 h OGTT between 140 and 200mg/dl. For
additional analyses, the cohort was also stratified into three groups
based on the M/I derived from the insulin clamp, witho5 indicating
insulin resistance and 47.5 corresponding to insulin sensitivity.
Because of the extreme skewness in the distribution of urinary
TGF-b1 values, the analyses were performed after log transformation
and results are expressed in terms of geometric means. The main
analyses included all repeated measurements for each subject (up to
three values for the OGTT, and up to two values for the insulin
clamp) and were based on mixed-effects linear regression. This is an
extension of ordinary linear regression that appropriately accounts for
the non-independence (within-subject correlation) of the repeated
measures and the unequal number of observations contributed by
each subject. The main results presented are from a model that also
controlled for age, sex, smoking, alcohol use, obesity status,
hypertension, and urine albumin excretion (UAE). All analyses were
carried out in SAS 9.1 (SAS Institute Inc., Cary, NC, USA).
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